STAAR Surgical (NASDAQ:STAA – Get Rating) – Equities researchers at William Blair lowered their Q2 2022 EPS estimates for STAAR Surgical in a research note issued to investors on Wednesday, May 11th. William Blair analyst A. Brackmann now expects that the medical instruments supplier will earn $0.19 per share for the quarter, down from their previous estimate of $0.21. William Blair also issued estimates for STAAR Surgical’s Q3 2022 earnings at $0.15 EPS, Q4 2022 earnings at $0.14 EPS, Q1 2023 earnings at $0.17 EPS, Q2 2023 earnings at $0.32 EPS and FY2023 earnings at $0.98 EPS.
A number of other equities research analysts have also recently issued reports on STAA. Canaccord Genuity Group upped their price objective on shares of STAAR Surgical from $81.00 to $89.00 and gave the stock a “buy” rating in a report on Tuesday, April 26th. Canaccord Genuity Group upped their price target on shares of STAAR Surgical from $81.00 to $89.00 and gave the company a “buy” rating in a report on Tuesday, April 26th. Needham & Company LLC restated a “buy” rating and set a $87.00 price target on shares of STAAR Surgical in a report on Tuesday, May 3rd. Benchmark upgraded shares of STAAR Surgical from a “hold” rating to a “buy” rating and set a $97.00 target price for the company in a research note on Monday, March 28th. Finally, StockNews.com initiated coverage on shares of STAAR Surgical in a research note on Thursday, March 31st. They issued a “hold” rating for the company. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, STAAR Surgical has an average rating of “Buy” and a consensus price target of $95.14.
STAAR Surgical (NASDAQ:STAA – Get Rating) last posted its quarterly earnings results on Wednesday, May 4th. The medical instruments supplier reported $0.21 earnings per share for the quarter, topping analysts’ consensus estimates of $0.10 by $0.11. STAAR Surgical had a net margin of 11.98% and a return on equity of 12.78%. The business had revenue of $63.20 million for the quarter, compared to the consensus estimate of $60.53 million. During the same period in the prior year, the business posted $0.13 earnings per share. STAAR Surgical’s revenue for the quarter was up 24.5% compared to the same quarter last year.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Allegheny Financial Group LTD acquired a new stake in shares of STAAR Surgical during the fourth quarter worth approximately $25,000. Rise Advisors LLC acquired a new stake in shares of STAAR Surgical during the fourth quarter worth approximately $25,000. Covestor Ltd acquired a new stake in shares of STAAR Surgical during the fourth quarter worth approximately $39,000. Lazard Asset Management LLC increased its holdings in shares of STAAR Surgical by 131.1% during the first quarter. Lazard Asset Management LLC now owns 684 shares of the medical instruments supplier’s stock worth $54,000 after buying an additional 388 shares in the last quarter. Finally, Lindbrook Capital LLC acquired a new stake in shares of STAAR Surgical in the fourth quarter valued at approximately $59,000. 89.93% of the stock is owned by institutional investors.
In related news, VP James E. Francese sold 922 shares of the stock in a transaction dated Monday, March 21st. The shares were sold at an average price of $74.62, for a total value of $68,799.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 3.60% of the company’s stock.
STAAR Surgical Company Profile (Get Rating)
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.
- Get a free copy of the StockNews.com research report on STAAR Surgical (STAA)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.